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Abstract
Background: Diabetic nephropathy is a serious complication of diabetes whose development process is associated
with inflammation, renal hypertrophy, and fibrosis. Coreopsis tinctoria Nutt, traditionally used as a healthcare tea, has
anti-inflammatory, anti-hyperlipidemia, and glycemic regulation activities. The aim of our study was to investigate the
renal protective effect of ethyl acetate extract of C. tinctoria Nutt (AC) on high-glucose–fat diet and streptozotocin
(STZ)-induced diabetic rats.
Methods: A diabetic rat model was induced by high-glucose–fat diet and intraperitoneal injection of 35 mg/kg STZ.
After treatment with AC at a daily dose of 150, 300 or, 600 mg/kg for 4 weeks, metabolic and renal function
parameters of serum and urine were examined. Degree of renal damage, renal proinflammatory cytokines, and fibrotic
protein expression were analyzed by histopathology and immunohistochemistry. Renal AMP-activated protein kinase
(AMPK) and transforming growth factor (TGF)-β1/Smad signaling pathway were determined by western blotting.
Results: Diabetic rats showed obvious renal dysfunction, inflammation and fibrosis. However, AC significantly reduced
levels of blood glucose, total cholesterol, triglyceride, blood urea nitrogen, serum creatinine and urinary albumin, as
well as expression of kidney proinflammatory cytokines of monocyte chemoattractant protein-1 and intercellular
adhesion molecule-1. AC also ameliorated renal hypertrophy and fibrosis by reducing fibronectin and collagen IV and
suppressing the TGF-β1/Smad signaling pathway. Meanwhile, AMPKα as a protective cytokine was markedly stimulated
by AC.
Conclusion: In summary, AC controls blood glucose, inhibits inflammatory and fibrotic processes, suppresses the TGF-β1/
Smad signaling pathway, and activates phosphorylation of AMPKα in the kidneys, which confirms the protective effects of
AC in the early stage of diabetic kidney disease.
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Background
As a result of socioeconomic development and lifestyle
changes, prevalence of diabetes has risen rapidly in the
past few decades. At present, diabetes has become a
major public health problem in China, and solutions are
urgently needed to prevent it as well as its complications
[1, 2].
Diabetic nephropathy (DN) is one of the major com-
plications of diabetes [3]. About 20 % of patients with
diabetes develop nephropathy after many years [4]. DN
is becoming a high-incidence cause of end-stage renal
disease (ESRD) in China and other countries [5, 6].
Many studies suggest that uncontrolled hyperglycemia
and hypertension may be risk factors for the develop-
ment of DN [7]. Hypertrophy of glomerular structures,
thickening of basement membranes, abnormal accumu-
lation of extracellular matrix (ECM) proteins, including
fibronectin and collagen, in the glomeruli, as well as
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persistent and slowly progressive proteinuria are the
typical traits of DN [8–11].
Although much attention has been paid to strictly
controlling blood glucose levels in diabetes, it is still
difficult to prevent kidney disease [12, 13]. The patho-
genesis of DN is complex and still not clear. However,
recent experimental and clinical research has demon-
strated that hyperglycemia induces renal oxidative stress,
inflammation, and lipid accumulation, which leads to
renal dysfunction by triggering multiple signaling path-
ways, and these may be crucial factors in pathogenesis of
DN [4, 14, 15].
Early diagnosis and preventive treatment is of major
importance for reducing morbidity and mortality of DN.
Although various interventions, such as angiotensin-
converting enzyme inhibitors, angiotensin receptor
blockers, vitamin D receptor agonist, or antihyperlipi-
demic agents are widely used, the rate of side effects and
cardiovascular morbidity remains high [16]. Recently,
traditional herbs have been used as effective comple-
mentary therapy in DN [17].
Coreopsis tinctoria Nutt is a plant of the genus Asteraceae
in the family of Compositae. The native species is from
North America, and then it spread worldwide. A large
amount of C. tinctoria Nutt is distributed in South
Xinjiang, China, where it is known as snow chrysanthe-
mum [18]. The dry flowers of this plant are traditionally
used as a healthcare tea to prevent cardiovascular disease
and diabetes. Recent research has shown that extract of C.
tinctoria Nutt has anti-inflammatory, anti-hyperlipidemia,
and glycemic regulation activities [19–21]. Since these
activities are closely related to metabolic regulation
and diabetic kidney protection, we tried to identify
the protective effect of ethyl acetate extract of C.
tinctoria Nutt (AC) on diabetic kidney disease, and
its possible mechanism of action.
Methods
Preparation of AC
C. tinctoria Nutt was harvested from Minfeng county,
Hetian city in Xinjiang province, China. The species was
identified by Professor Junping Hu, College of Pharmacy,
Xinjiang Medical University. The geographic coordinates
of planted C. tinctoria Nutt was 82°, 22 ′, 00″–85°, 55′,
00 ″ of east longitude and 35°, 20 min, 00 s to 39°,
30 min, 00 s of north latitude. A voucher specimen of
the plant material used in our study has been deposited
in the herbarium of Ethnomedicine Research Institution
in Urumuqi, Xinjiang province (No.20120715278). The
dried flowers of C. tinctoria Nutt (160 g) were ground
into powder and placed in 4 L of 55 % ethanol for reflux
extraction twice at 80 °C for 2 h. The extracting liquid
was filtered, merged, and then concentrated by rotary
evaporator (R-210; Buchi, Essen, Germany) into 1 L
liquid extract. An equal volume of AcOEt was added
into the 1 L of liquid extract and than was concentrated
and spray dried to obtain the powder of AC (4.4 %, w/w:dry
flower). The powder of AC and metformin were weighed
and dissolved in distilled water containing 1 % (g/100 mL)
sodium carboxymethyl cellulose and ultrasonicated for 4 h
until the powder was completely dissolved.
Analysis of AC by HPLC/MS
AC was analyzed by HPLC (Waters 2690) with a
diode-array detector (Waters 2487) scanning from
200–600 nm. Ethyl acetate extract was seperated by
Shim-pack VP-ODS column (150 × 4.6 mm, 5 μm)
with the optimum condition as described previously
[20]. The mobile phase contained solution A of 0.5 %
formic acid and solution B of acetonitrile, with a column
temperature of 35 °C and flow rate of 0.3 mL/min. The
elution program was as follows: 95 %–80 % of solution A
and 5 %–20 % of solution B during the first 1 h;
80 %–60 % of solution A and 20 %–40 % of solution
B for the remaining 50 min. A mass spectrometer
(LCQ-DecA XP MAX Thermo) with a negative electro-
spray ionization mode was used. Mass spectrometer
conditions were maitainted with a source temperature of
100 °C, desolvation temperature of 350 °C, desolvation gas
flow of 600 L/h, capillary voltage of 3 kV, and cone voltage
of 30 V. Mass scan range was from 100 to 800 m/z.
Animal models
Healthy male Sprague–Dawley rats (8–10 weeks old,
weighing 200–250 g) were obtained from the Animal
Centre, Xinjinag Medical University (No. of Certification:
65000700000045). The study was authorized by the
Institutional Animal Care and Use Committee of First
Affiliated Hoapital of Xinjiang Medical University
(Approval No.: IACUC-20140304011). The animals
were kept in a specific pathogen free environment at
22 ± 2 °C and 45 ± 5 % humidity for 2 weeks of
acclimatization. Then, they were randomly divided
into two groups and fed with normal diet and high-
fat diet (67 % normal diet, 20 % sucrose, 10 % fatty
oil, 2.5 % cholesterol, and 0.8 % sodium cholate).
After 8 weeks feeding, the rats were fasted overnight
and injected intraperitoneally with 35 mg/kg strepto-
zotocin (STZ) dissolved in 0.1 M citric acid and
0.1 M sodium phosphate solution, pH 4.5. The dia-
betic model was confirmed after 72 h by a glucose
level ≥16.7 mmol/L. Animals were fed with high-fat
diet until the end of the experiment.
Experimental design
Animals were randomly divided into six groups of ten
according to the weight and blood glucose levels as
follows: Group 1 (NC): normal control rats with distilled
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water containing 1 % (g/100 mL) sodium carboxymethyl
cellulose per day by gavage administration for 4 weeks;
Group 2 (DC): diabetic control rats with distilled water
containing 1 % (g/100 mL) sodium carboxymethyl cellulose
per day by gavage administration for 4 weeks; Groups 3, 4
and 5 (DC + AC150, DC + AC300 and DC + AC600):
diabetic rats with 150, 300 and 600 mg/kg AC per
day, respectively, by gavage administration for 4 weeks;
Group 6 (DC +M): diabetic rats with 200 mg/kg met-
formin per day by gavage administration for 4 weeks.
At day 27 of adminstration, 24 h urine samples from
rats housed in metabolic cages were centrifuged and
collected. At the end of the experiments, all the animals
were killed by 10 % chloral hydrate. All the blood
samples were collected. The right kidneys were rinsed
with cold isotonic saline and placed immediately in
liquid nitrogen, and then stored at −80 °C for testing.
The left kidneys were weighed and fixed in 10 % formal-
dehyde solution.
Blood sampling and analysis
The collected blood samples were centrifuged at
1000 g for 20 min. Serum samples were separated for
detection of blood glucose, total cholesterol (TC),
triglycerides, blood urea nitrogen (BUN), and serum
creatinine (SCr) by an automatic biochemical analyzer
(BS-120; Mindray, China).
Urinalysis
Urine albumin levels were measured using a kit obtained
from Nanjing Jiancheng Bioengineering Institute, China.
Histopathological analysis
Left kidney tissues were fixed in 10 % formaldehyde
solution, embedded in paraffin, and cut into 4 μm sec-
tions. The tissue sections were stained with hematoxylin
and eosin (H&E), and Masson’s reagent. Images were
captured by a light microscope (SZX7-1093; Olympus,
Japan). The mesangial expansion index from 30 glom-
eruli of each rat was graded in four levels from 0 to 3
[22]: 0, normal glomerulus; 1, matrix expansion occurred
in up to 50 % of a glomerulus; 2, matrix expansion
occurred in 50 %–75 % of a glomerulus; and 3, matrix
expansion occurred in 75 %–100 % of a glomerulus, and
the means were caculated and compared. For Masson’s
stain, 4° of fibrosis from 30 glomeruli of each rat were
scored by measuring the percentage area of blue staining
as follows: 0, absent or < 25 %; 1, 25 %–50 %; 2,
50 %–75 %; and 3, > 75 %. The slides from all the
animals were evaluated by a pathologist who was
unaware of the experimental details.
Immunohistochemical analysis
After deparaffinization and hydration, the paraffin em-
bedded tissue sections were washed three times with
phosphate-buffered saline (PBS). Endogenous peroxidase
activity was quenched by incubating the slides in
methanol solution containing 3 % H2O2. After wash-
ing three times in distilled water and PBS, goat serum
(Bioss Biotechnology, Beijing, China) was used to
block the nonspecific binding sites for 30 min. The
primary antibodies [TGF-β1, 1:500; monocyte chemo-
attractant protein (MCP)-1, 1:500; intercellular adhesion
molecule (ICAM)-1, 1:500; fibronectin, 1:1000; Collagen
IV, 1:1000; Abcam, Cambridge, MA, USA) were incubated
and reacted at 4 °C overnight. On the next day, the
secondary horseradish-peroxidase-conjugated antibody
(Bioss Biotechnology) was added and reacted for 30 min
at 37 °C. After washing three times with PBS, tissue
sections were immunostained with diaminobenzidine
tetrahydrochloride as the substrate and hematoxylin as
the counterstain. Negative control slices were made in the
same way except for the first antibody. Four degrees of
TGF-β1, MCP-1, ICAM-1, Collagen IV and fibronectin
expression in 30 glomeruli from each rat were graded by
measuring the percentage area of positive staining as
follows: 0, absent or < 25 %; 1, 25 %–50 %; 2, 50 %–75 %;
and 3, > 75 %. The slides from all the animals were
evaluated by a pathologist who was unaware of the experi-
mental details.
Western blot analysis
The right kidneys were extracted with RIPA lysis buf-
fer (Thermo, USA) containing a protease and phos-
phatase inhibitor cocktail to obtain the protein lysate.
The concentration of the protein lysate was measured
by BCA Protein Assay Kit (Thermo). Protein lysate
(20 μg) from each sample was separated by 12 %
SDS-PAGE at 80 V and transferred onto PVDF mem-
brane (Millpore, USA). After blocking in 5 % (v/v)
skimmed milk and Tris-buffered saline Tween (TBST)
for 1 h and washing three times in TBST, the trans-
ferred membranes were incubated with the primary
antibodies of TGF-β1, β-actin (1:1000; Abcam);
Smad2, p-Smad2, AMP-activated protein kinase
(AMPK)α, p-AMPKα, and GAPDH (1:1000; Cell Sig-
naling Technology, Danvers, MA, USA) at 4 °C over-
night. The probed membranes were washed three times
in TBST and combined with alkaline-phosphatase-
conjuated secondary antibody (Invitrogen, Carlsbad, CA,
USA) for 1 h at 37 °C. The protein band was colored by
BCIP/NBT Substrate Kit (Invitrogen) and the band dens-
ity was scanned and calculated by Quantity One v4.62
software.
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Fig. 1 HPLC/MS analysis of AC. a HPLC analysis of AC at 280 nm wavelength. Four main compounds were (P1) chlorogenic acid, (P2) flavanomarein,
(P3) marein, and (P4) 4,5-dicaffeoyl-quinic acid. Precursor ion (left) and product ion (right) of (b) chlorogenic acid, (c) flavanomarein, (d) marein, and
(e) 4,5-dicaffeoyl-quinic acid
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Statistical analysis
All data are presented as the mean ± SEM. Differences
between multiple groups were analysed by one-way
analysis of variance followed by Duncan’s multiple
range test. Differences between two groups were
measured by Student’s t test using SPSS v16.0 soft-
ware (Chicago, IL, USA). Data were considerd statisti-
cally significant at P < 0.05.
Results
HPLC/MS analysis of AC
The main compounds and their relative content were
analyzed by HPLC/MS. As shown in Fig. 1 and Table 1,
we identified chlorogenic acid, flavanomarein, marien,
and 4,5-dicaffeoyl-quinic acid and determined their
relative content.
Change in body weight and metabolic parameters after
treatment with AC
Diabetes was defined as blood glucose level ≥ 16.7 mmol/L
in a random blood glucose test. The DC group had a sig-
nificantly higher average random blood glucose level of
30.05 mmol/L (Table 2). However, after 4 weeks of treat-
ment, the random blood glucose level in the positive con-
trol group (P < 0.05) and the low-dose AC group (P < 0.01)
was significantly decreased. By contrast, body weight and
serum insulin of the DC group were significantly de-
creased compared with those in the normal group.
Treatment with 150 mg/kg AC alleviated the body
weight (P < 0.05) and 600 mg/kg AC (P < 0.05) allevi-
ated serum insulin loss. It was noteworthy that
dyslipidemia appeared in the DC, DC + AC150 and
DC + AC600 groups. The later two groups were found
to ameliorate abnormity of TG and TC.
Effect of AC on renal function
Kidney/weight ratio (K/W) of diabetic rats was markedly
higher than in normal rats (Table 3). K/W only de-
creased significantly in the DC + AC600 group (P < 0.05).
Twenty-four-hour urine volume was higher in diabetic
than normal rats. There was no significant change in
24 h urine volume apart from in the DC + AC150 group
(P < 0.05). In diabetic rats, mean BUN, SCr and albumin-
uria were notably increased in comparison with normal
rats. Compared with diabetic rats, BUN level in the DC +
AC300, DC +AC600 and DC +M groups was significantly
decreased (P < 0.05). SCr level in all the treatment groups
was significantly decreased, with a greater decrease in the
DC + 150 group (P < 0.01). Albuminuria was significantly
ameliorated in the DC +AC600 group (P < 0.01).
Effect of AC on renal histology
H&E and Masson’s stain were used to detect renal
histology characteristics. Judging from H&E staining,
glomerular and tubular lesions in the normal group were
not obvious. The DC group showed a dramatic increase
in mesangial matrix and basement membrane thickening,
both in glomerular and tubular lesions (Fig. 2a). There
was some improvement after treatment with 150 mg/kg AC
(P < 0.05), 300 mg/kg AC (P < 0.05), 600 mg/kg AC (P <
0.01) and 200 mg/kg metformin (P < 0.05). Collagen depos-
ition was determined by Masson’s stain. Heavy collagen de-
position was clearly observed in the DC group. This
abnormality was ameliorated after treatment with AC
(150 mg/kg, P < 0.05; 300 mg/kg, P < 0.05; and 600 mg/kg,
P < 0.01) and metformin (200 mg/kg, P < 0.01). These
results confirmed the protective effect of AC and metfor-
min on diabetic renal damage.
Effect of AC on renal TGF-β1, MCP-1, ICAM-1, collagen IV
and fibronectin expression
To investigate the anti-inflammatory and anti-fibrotic
effects of AC, immunohistochemistry was used to deter-
mine protein expression of TGF-β1, MCP-1, ICAM-1,
collagen IV and fibronectin in diabetic kidney. Positive
expression was stained brown–yellow (Figs. 3a and 4a).
Compared with the NC group, the DC group showed
significant overexpression of the five cytokines (Figs. 3b
and 4b; P < 0.01). All cytokine expression was decreased
to some extent after AC and metformin treatment. AC
600 mg/kg had the most inhibitory effect of protein
expression of TGF-β1, MCP-1, ICAM-1, collagen IV and
fibronectin. These results indicate that AC has a protect-
ive effect on diabetic renal inflammation and fibrosis.
AC ameliorates renal inflammation and fibrosis by
activing AMPK and suppressing TGF-β1/Smad signaling
pathway
To elucidate the mechanism of the anti-inflammatory
and antifibrotic effects of AC, the TGF-β1/Smad and
AMPK signaling pathways were investigated by western
blotting. The TGF-β1/Smad signaling pathway was
Table 1 Analysis of relative quantity and compound identification of AC
Peak no. Compund identification Rt (min) Relative content (mg/g) Precursor ion (m/z) Product ion (m/z) Molecular weight
P1 Chlorogenic acid 17.76 4.08 354 353 191
P2 Flavanomarein 26.3 34.73 450 449 431,287
P3 Marien 46.55 181.61 450 449 431,287
P4 4,5-dicaffeoyl-quinic acid 52.66 100.51 516 515 353
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considered to play a vital role in progression of renal
fibrosis. As shown in Fig. 5a, b, TGF-β1 expression in
diabetic rats was significantly increased, followed by
overexpression of phospho (p)-Smad2. Whereas, TGF-β1
and p-Smad2 expression was markedly decreased by
treatment with AC. The active form of AMPKα was
more highly expressed in normal rats than diabetic rats
(P < 0.01). Treatment with AC (150, 300 and 600 mg/kg)
and metformin significantly upregulated the p-AMPKα
expression (Fig. 6a, b). These results indicated that the
anti-inflammatory and antifibrotic effects of AC were
possibly related to TGF-β1/Smad and AMPK signaling
pathways.
Discussion
In present study, we demonstrated the renal protective
effect of AC in diabetic rats. After treatment with AC
for 4 weeks, both glucose and lipid metabolism disorders
were ameliorated. Biochemical markers of renal function,
such as albuminuria, BUN, SCr, K/W ratio and 24 h urine
volume, as well as renal structural abnormalities and
fibrosis, were significantly improved by AC treatment. We
also demonstrated that AC inhibited renal inflammatory
and fibrotic reactions and upregulated p-AMPKα expres-
sion, which suggests that the positive effects of AC in
diabetic nephropathy are multifactorial.
The animal model of high-fat diet combined with
STZ-induced diabetes manifests many characteristics of
human diabetes, such as hyperglycemia, hyperlipemia,
lack of insulin secretion, and loss of body weight.
Furthermore, kidney disease develops under these condi-
tions. Compared with normal rats, diabetic rats showed
significant increases in albuminuria, BUN, SCr, K/W
ratio and 24 h urine volume, along with renal inflamma-
tion and renal structural abnormalities and fibrosis,
which indicated that the diabetic renal injury model was
successfully formed.
Previous studies that demonstrated the anti-hyperlipemia
and glycemic regulation activities of C. tinctoria Nutt
[19, 20] were confirmed by our results. After treat-
ment with low—and high-dose AC for 4 weeks, TC
and triglyceride levels were significantly decreased.
Blood glucose was only decreased in the low-dose AC
group, and insulin secretion was only increased in the
high-dose AC and metformin groups. It was surpris-
ing that the middle dose of AC had no effect on body
weight and metabolic parameters, even when it ame-
liorated renal effects. The low dose of AC had a
better effect on lipid regulation than the high dose
had, even if there was less renal damage than with
high dose AC. Further research is needed to reveal
the relationship bewteen different doses of AC and
their renal protective effect. Renal function parame-
ters were improved by all three doses of AC. These
results indicate that the protective effect of AC on
DN is not only mediated by glycemic regulation, but
also by multiple synergistic effects.
Inflammation has emerged as an important factor in
understanding the pathogenic mechanism of DN. Acti-
vation of the inflammatory response, leading to upregu-
lation of various inflammatory cytokines, chemokines,
growth factors, adhesion molecules, and nuclear factors,
is a common pathway for progression of DN in humans
and in animal models [14, 15]. MCP-1 is an important
Table 2 Changes in body weight and metabolic parametres in each group
Group Body weigh (g) Plasma glucose (mmol/L) TC (mmol/L) TG (mmol/L) Serum insulin (μU/mL)
NC (n = 10) 584.80 ± 13.76 7.10 ± 0.12 1.42 ± 0.11 1.58 ± 0.07 61.23 ± 2.51
DC (n = 8) 344.25 ± 15.22# 30.05 ± 0.62# 7.58 ± 0.23# 23.78 ± 1.79# 26.25 ± 1.85#
DC + AC150(n = 10) 390.80 ± 10.88* 21.67 ± 1.79** 2.11 ± 0.33** 7.09 ± 1.17** 23.25 ± 1.47
DC + AC300(n = 7) 386.86 ± 17.62 30.9 ± 0.55 7.34 ± 0.26 20.27 ± 2.9 23.86 ± 1.30
DC + AC600(n = 9) 374.22 ± 12.25 29.1 ± 0.50 4.23 ± 0.26* 18.48 ± 1.53* 31.91 ± 1.34*
DC +M(n = 10) 379.1 ± 11.49 27.31 ± 0.68* 4.31 ± 0.20** 17.22 ± 0.90* 22.62 ± 1.00
Data expressed as mean ± SEM (n = 7–10). #P < 0.01 versus normal group; *P < 0.05 versus control group; **P < 0.01 versus control group
Table 3 Changes in parametres of renal function in each group
Group K/W (mg/g) 24 h urine volume (mL/day) BUN(mmo/L) SCr(μmol/L) Urine albumin (mg/24 h)
NC(n = 10) 2.80 ± 0.07 18.5 ± 1.85 6.26 ± 0.14 102.53 ± 0.86 4.95 ± 0.81
DC(n = 8) 5.15 ± 0.10# 157.88 ± 4.56# 15.96 ± 0.93# 128.56 ± 6.08# 34.59 ± 2.42#
DC + AC150(n = 10) 4.80 ± 0.17 133.89 ± 9.35* 13.05 ± 1.14 94.63 ± 2.20** 30.73 ± 1.53
DC + AC300(n = 7) 5.01 ± 0.27 142.86 ± 8.08 11.59 ± 1.5* 118.43 ± 4.98* 28.40 ± 1.44*
DC + AC600(n = 9) 4.71 ± 0.16* 144.50 ± 7.54 13.37 ± 0.70* 105.60 ± 4.59* 26.75 ± 2.32**
DC +M(n = 10) 5.03 ± 0.17 143.70 ± 5.97 12.52 ± 1.13* 103.04 ± 3.46* 27.89 ± 1.74*
Data expressed as mean ± SEM (n = 7–10). #P < 0.01 versus normal group; *P < 0.05 versus control group; **P < 0.01 versus control group
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inflammatory cytokine that takes part in the develop-
ment of DN. Evidence demonstrates that metabolic
disorders induced by diabetes could drive MCP-1 activa-
tion and accelerate macrophage recruitment from the
circulation to the kidneys. Meanwhile, high expression
of MCP-1 aggravates ECM accumulation and protein ex-
cretion in glomeruli, tubules and interstitium, by
activating overexpression of other proinflammatory cyto-
kines [23, 24]. Also, MCP-1 can modulate mesangial
matrix accumulation by TGF-β1 production without af-
fecting glomerular macrophage accumulation [25].
ICAM-1 is a cell surface glycoprotein that is expressed
on kidney endothelial, epithelial and mesangial cells and
leukocytes. ICAM-1 promotes macrophage infiltration
Fig. 2 Renal histology after treatment with or without AC and metformin. a Pathological features of the left kidney tissue stained with H&E and Masson
stain (orginal magnification 400×). Each photomicrograph represented the pathological feature of four rats from each group. b Matrix expansion and area
of fibrosis among the groups were semiquantitatively analyzed. Values were expressed as mean ± SEM (n = 4). #P < 0.01 versus normal group;
*P < 0.05 versus control group; **P < 0.01 versus control group
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in glomeruli and interstitium, which is thought to play a
crucial role in renal injury and proteinuria. Although the
precise role of ICAM-1 in the development of DN has
not been fully investigated, accumulating evidence has
confirmed a close relationship. Proteinuria increases
with overexpression of ICAM-1, which indicates that
ICAM-1 could be a useful biomarker for prediction of
DN [26]. Consistent with these studies, we found that
both MCP-1 and ICAM-1 expression was markedly
increased in rat diabetic kidneys, While AC treatment
dramatically decreased both MCP-1 and ICAM-1
expression. These results indicate the renal improvement
effect of AC is possibly mediated by its anti-inflammatory
activity.
A large body of evidence shows that TGF-β1 is a key
participant in the cascade of events of kidney sclerosis.
Fig. 3 Expression of TGF-β1, MCP-1 and ICAM-1 in kidney. a Immunohistochemistry of TGF-β1, MCP-1 and ICAM-1 (orginal magnification 400×). b
TGF-β1, MCP-1 and ICAM-1 expression was semiquantitatively analyzed. Values were expressed as mean ± SEM (n = 4). #P < 0.01 versus normal
group; *P < 0.05 versus control group; **P < 0.01 versus control group
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Overexpression of TGF-β1 in diabetic kidney promotes
cellular hypertrophy, stimulates ECM biosynthesis, and
induces renal scarring in experimental and human DN
[27, 28]. It is well established that TGF-β1 exerts its
biological effects by activating downstream mediators of
Smad2 and Smad3. The activated Smad2 and Smad3
subsequently bind to Smad4 to form the Smad complex,
which translocates into the nucleus, and regulates target
Fig. 4 Expression of collagen IV and fibronectin in kidney. a Immunohistochemistry of collagen IV and fibronectin (orginal magnification
400×). b Collagen IV and fibronectin expression was semiquantitatively analyzed. Values were expressed as mean ± SEM (n = 4). #P < 0.01
versus normal group; *P < 0.05 versus control group; **P < 0.01 versus control group
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gene transcription, in conjunction with other nuclear
cofactors [29–31]. Therefore, modulation of TGF-β1
expression could be regarded as an effective therapeutic
strategy for kidney diseases [29]. We showed that rats
with STZ-induced diabetes had high expression of TGF-
β1, major mesangial matrix expansion, and heavy colla-
gen deposition, as well as overexpression of fibronectin
and collagen IV. These results are in accordance with a
previous study that showed a close relationship between
overexpression of TGF-β1 and renal morphological
changes and fibrosis [28]. Diabetic rats with AC treat-
ment showed downregulation of TGF-β1, fibronectin
and collagen IV, as well as fewer renal lesions compared
with untreated diabetic rats.
AMPK acts as an energy sensor in cellular responses
by raising intracellular AMP and lowering ATP [32, 33].
AMPK consists of three subunits, designated α, β and γ.
The α subunit of AMPK contains the catalytic domain,
which has two isoforms, α1 and α2. The active form of
AMPK depends on the phosphorylation of threonine-
172 of the α subunit [34]. Activity of AMPK in the
kidneys could be mediated by conditions of metabolic
stress, such as diabetes or obesity [35]. Increasing evi-
dence demonstrates that suppression of phosphorylation
Fig. 5 Effect of AC on protein expression of TGF-β1, Smad2 and p-Smad2. a TGF-β1, Smad2 and p-Smad2 expression in right kidney. b Band density
analysis of TGF-β1, Smad2 and p-Smad2. Values were expressed as mean ± SEM (n = 4). #P< 0.01 versus normal group; *P< 0.05 versus control group;
**P< 0.01 versus control group
Fig. 6 Effect of AC on protein expression of AMPK and p-AMPK. a AMPKand p-AMPK levels in right kidney. b Band density analysis of TGF-β1, AMPK
and p-AMPK. Values were expressed as mean ± SEM (n = 3). #P < 0.01 versus normal group; *P < 0.05 versus control group; **P < 0.01 versus
control group
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of AMPK in animal models of diabetes is involved in the
pathogenesis of kidney disease through multiple path-
ways [36]. Recent studies have demonstrated that
AMPK is closely related to renal inflammation and fi-
brosis [37, 38]. In vitro and in vivo experiments have
confirmed that the reduction in AMPK phosphoryl-
ation could exacerbate abnormal ECM protein synthe-
sis and renal hypertrophy by stimulating mammalian
target of rapamycin activity and TGF-β1/Smad4 sig-
naling pathway [39, 40]. Furthermore, a renal anti-
inflammatory effect of active AMPK by suppression of
proinflammatory cytokines such as MCP-1 has been iden-
tified [35, 39]. Consistently, AMPK agonists of 5-
Aminoimidazole-4-carboxyamide.
Ribonucleoside(AICAR) and metformin inhibit diabetes-
induced renal hypertrophy and inflammation response
beyond their effect on hyperglycemia [36]. Therefore,
AMPK could be a target for renal protection in diabetic
models. Our experiments showed a marked decrease in
p-AMPKα expression, along with aggravation of renal
inflammation and fibrosis in diabetic rats, which was
consistent with previous studies. However AC and met-
formin treatment significantly increased p-AMPKα
expression and ameliorated renal inflammation and
fibrosis. Further investigation of the effect of AC on
AMPK signaling pathway is needed.
Conclusion
Our results demonstrate that the renal protective effect
of AC in rats with high-glucose–fat diet and STZ-induced
diabetes is partially mediated by anti-hyperglycemic
activity and partially by anti-inflammatory and antifi-
brotic activity via AMPK and the TGF-β1/Smad
signaling pathway. However, due to the multiple
compounds in AC that exert biological activities,
further study is necessary to clarify the mechanism of
the anti-inflammatory and antifibrotic effects of AC
and its main components on DN.
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